Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis Report By Product (Personalized and Off-The-Shelf Neoantigen Vaccines), By Neovaccine Type, By Therapeutic Area, By Therapy Type, Region And Segment Forecasts, 2025-2034

Report Id: 1117 Pages: 180 Last Updated: 22 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Neoantigen Cancer Vaccine Market Segmentation

Global Neoantigen Cancer Vaccine Market by Product

  • Personalized Neoantigens vaccines
  • Off-the-shelf Neoantigen vaccines

Neoantigen Cancer Vaccine Market

Global Neoantigen Cancer Vaccine Market Based on Neovaccine Type

  • Nucleic acid/DNA/mRNA Vaccine
  • Peptide Vaccines
  • Dendritic Cell–based Vaccines

Global Neoantigen Cancer Vaccine Market Based on Therapy Type

  • Mono Therapeutic Regimens
  • Combinatorial Regimens

Global Neoantigen Cancer Vaccine Market Based on Region

Europe Neoantigen Cancer Vaccine Market Outlook, 

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Neoantigen Cancer Vaccine Market Outlook,

  • U.S.
  • Canada

Asia Pacific Neoantigen Cancer Vaccine Market Outlook,

  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Neoantigen Cancer Vaccine Market Snapshot

Chapter 4.          Global Neoantigen Cancer Vaccine Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Trends

4.5.        Investment and Funding Analysis

4.6.        Porter's Five Forces Analysis

4.7.        Incremental Opportunity Analysis (US$ MN), 2024-2034

4.8.        Global Neoantigen Cancer Vaccine Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034

4.9.        Competitive Landscape & Market Share Analysis, By Key Player (2024)

4.10.     Use/impact of AI on Neoantigen Cancer Vaccine Market Industry Trends

Chapter 5.          Neoantigen Cancer Vaccine Market Segmentation 1: By Product, Estimates & Trend Analysis

5.1.        Market Share by Product, 2024 & 2034

5.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:

5.2.1.    Personalized Neoantigens vaccines

5.2.2.    Off-the-shelf Neoantigen vaccines

Chapter 6.          Neoantigen Cancer Vaccine Market Segmentation 2: By Neovaccine Type, Estimates & Trend Analysis

6.1.        Market Share by Neovaccine Type, 2024 & 2034

6.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Neovaccine Type:

6.2.1.    Nucleic acid/DNA/mRNA Vaccine

6.2.2.    Peptide Vaccines

6.2.3.    Dendritic Cell–based Vaccines

Chapter 7.          Neoantigen Cancer Vaccine Market Segmentation 3: By  Therapy Type, Estimates & Trend Analysis

7.1.        Market Share by  Therapy Type, 2024 & 2034

7.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following  Therapy Type:

7.2.1.    Mono Therapeutic Regimens

7.2.2.    Combinatorial Regimens

Chapter 8.          Neoantigen Cancer Vaccine Market Segmentation 4: Regional Estimates & Trend Analysis

8.1.        Global Neoantigen Cancer Vaccine Market, Regional Snapshot 2024 & 2034

8.2.        North America

8.2.1.    North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

8.2.1.1. US

8.2.1.2. Canada

8.2.2.    North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034

8.2.3.    North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034

8.2.4.    North America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by  Therapy Type, 2021-2034

8.3.        Europe

8.3.1.    Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

8.3.1.1. Germany

8.3.1.2. U.K.

8.3.1.3. France

8.3.1.4. Italy

8.3.1.5. Spain

8.3.1.6. Rest of Europe

8.3.2.    Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034

8.3.3.    Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034

8.3.4.    Europe Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by  Therapy Type, 2021-2034

8.4.        Asia Pacific

8.4.1.    Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

8.4.1.1. India

8.4.1.2. China

8.4.1.3. Japan

8.4.1.4. Australia

8.4.1.5. South Korea

8.4.1.6. Hong Kong

8.4.1.7. Southeast Asia

8.4.1.8. Rest of Asia Pacific

8.4.2.    Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034

8.4.3.    Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034

8.4.4.    Asia Pacific Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts By  Therapy Type, 2021-2034

8.5.        Latin America

8.5.1.    Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

8.5.1.1. Brazil

8.5.1.2. Mexico

8.5.1.3. Rest of Latin America

8.5.2.    Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034

8.5.3.    Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034

8.5.4.    Latin America Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by  Therapy Type, 2021-2034

8.6.        Middle East & Africa

8.6.1.    Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

8.6.1.1. GCC Countries

8.6.1.2. Israel

8.6.1.3. South Africa

8.6.1.4. Rest of Middle East and Africa

8.6.2.    Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034

8.6.3.    Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by Neovaccine Type, 2021-2034

8.6.4.    Middle East & Africa Neoantigen Cancer Vaccine Market Revenue (US$ Million) Estimates and Forecasts by  Therapy Type, 2021-2034

Chapter 9.          Competitive Landscape

9.1.        Major Mergers and Acquisitions/Strategic Alliances

9.2.        Company Profiles

9.2.1.    Roche

9.2.1.1. Business Overview

9.2.1.2. Key Product/Service 

9.2.1.3. Financial Performance

9.2.1.4. Geographical Presence

9.2.1.5. Recent Developments with Business Strategy

9.2.2.    Medimmune

9.2.3.    Moderna Therapeutics/Merck

9.2.4.    Advaxis

9.2.5.    Agenus

9.2.6.    Genocea Biosciences Inc

9.2.7.    Gritstone Oncology

9.2.8.    Neon Therapeutics

9.2.9.    Nouscom

9.2.10.  OSE Immunotherapeutics

9.2.11.  Immunovative Therapeutics

9.2.12.  Medigene

9.2.13.  Vaccibody

9.2.14.  Brightpath Biotherapeutics

9.2.15.  Geneos Therapeutics

9.2.16.  Frame Therapeutics

9.2.17.  Immunetune

9.2.18.  NeoPhore

9.2.19.  CureVac AG

9.2.20.  Other Prominent Players 

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4195
Security Code field cannot be blank!

Frequently Asked Questions

Global Neoantigen Cancer Vaccine Market is expected to grow at a 20.0% CAGR during the forecast period for 2025-2034.

Moderna Therapeutics/Merck, Advaxis, Agenus, Genocea Biosciences Inc, Gritstone Oncology, Neon Therapeutics, Nouscom, OSE Immunotherapeutics, Immunova

Product, Neovaccine Type, Therapeutic Area and Therapy Type are the key segments of the Neoantigen Cancer Vaccine Market.

North American region is leading the Neoantigen Cancer Vaccine Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying